Anti-inflammatory effect of combination therapy with rosiglitazone and all-trans retinoic acid on high glucose-induced MCP-1 response in rat mesangial cells

Dae Hee Kim, Geon Cheol Lee, Cy Hyun Kim, Se Won Oh, Kum Hyun Han, Sang Youb Han

Research output: Contribution to journalArticle

Abstract

Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) agonists and retinoid acid have anti-inflammatory and anti-proliferative effects; however, their synergistic effects are not well known. We investigated the combined anti-inflammatory effect of rosiglitazone, which is a PPAR-γ agonist, and retinoid acid in rat mesangial cells (RMCs) stimulated by a high glucose (HG) concentration (30 mmol of D-glucose). The doses of rosiglitazone and all-trans retinoic acid (ATRA) which inhibited MCP-1 mRNA expression by 20-40% were selected for the study. At 48 h following incubation of RMCs in HG, MCP-1 mRNA expression was significantly increased. Rosiglitazone and ATRA lowered MCP-1 mRNA expression in a dose-dependent manner. Among the effective doses, 1.0 and 5.0 μmol/L of rosiglitazone, and 0.1 and 1.0 μmol/L of ATRA were selected for further studies. HG-induced MCP-1 mRNA expression was inhibited by combined treatment with rosiglitazone and ATRA. A combination of 1.0 μmol/L rosiglitazone and 0.1 μmol/L ATRA tended to decrease MCP-1 mRNA expression compared to the individual treatments. A combination of 5.0 μmol/L rosiglitazone and 1.0 μmol/L ATRA significantly inhibited MCP-1 mRNA expression. MCP-1 protein levels were significantly increased after 48 h of incubating the RMCs in HG. The 5.0 μmol/L dose of rosiglitazone significantly lowered MCP-1 protein synthesis while 1 μmol/L ATRA decreased MCP-1 expression stimulated by HG. Combined treatment with rosiglitazone and ATRA caused a larger decrease in MCP-1 protein synthesis compared to either treatment alone. In conclusion, the data obtained show the possibility of a synergistic effect on MCP-1 mRNA expression by rosiglitazone and ATRA.

Original languageEnglish
Pages (from-to)463-467
Number of pages5
JournalBiomedical Research (India)
Volume28
Issue number1
Publication statusPublished - 2017 Jan 1
Externally publishedYes

Fingerprint

rosiglitazone
Mesangial Cells
Tretinoin
Rats
Anti-Inflammatory Agents
Glucose
Messenger RNA
Therapeutics
Peroxisome Proliferator-Activated Receptors
Retinoids
Proteins
Acids

Keywords

  • Inflammation
  • MCP-1
  • Mesangial cell
  • Retinoic acid
  • Rosiglitazone

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Anti-inflammatory effect of combination therapy with rosiglitazone and all-trans retinoic acid on high glucose-induced MCP-1 response in rat mesangial cells. / Kim, Dae Hee; Lee, Geon Cheol; Kim, Cy Hyun; Oh, Se Won; Han, Kum Hyun; Han, Sang Youb.

In: Biomedical Research (India), Vol. 28, No. 1, 01.01.2017, p. 463-467.

Research output: Contribution to journalArticle

@article{8afc64655daf471997eaa9a560a406f7,
title = "Anti-inflammatory effect of combination therapy with rosiglitazone and all-trans retinoic acid on high glucose-induced MCP-1 response in rat mesangial cells",
abstract = "Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) agonists and retinoid acid have anti-inflammatory and anti-proliferative effects; however, their synergistic effects are not well known. We investigated the combined anti-inflammatory effect of rosiglitazone, which is a PPAR-γ agonist, and retinoid acid in rat mesangial cells (RMCs) stimulated by a high glucose (HG) concentration (30 mmol of D-glucose). The doses of rosiglitazone and all-trans retinoic acid (ATRA) which inhibited MCP-1 mRNA expression by 20-40{\%} were selected for the study. At 48 h following incubation of RMCs in HG, MCP-1 mRNA expression was significantly increased. Rosiglitazone and ATRA lowered MCP-1 mRNA expression in a dose-dependent manner. Among the effective doses, 1.0 and 5.0 μmol/L of rosiglitazone, and 0.1 and 1.0 μmol/L of ATRA were selected for further studies. HG-induced MCP-1 mRNA expression was inhibited by combined treatment with rosiglitazone and ATRA. A combination of 1.0 μmol/L rosiglitazone and 0.1 μmol/L ATRA tended to decrease MCP-1 mRNA expression compared to the individual treatments. A combination of 5.0 μmol/L rosiglitazone and 1.0 μmol/L ATRA significantly inhibited MCP-1 mRNA expression. MCP-1 protein levels were significantly increased after 48 h of incubating the RMCs in HG. The 5.0 μmol/L dose of rosiglitazone significantly lowered MCP-1 protein synthesis while 1 μmol/L ATRA decreased MCP-1 expression stimulated by HG. Combined treatment with rosiglitazone and ATRA caused a larger decrease in MCP-1 protein synthesis compared to either treatment alone. In conclusion, the data obtained show the possibility of a synergistic effect on MCP-1 mRNA expression by rosiglitazone and ATRA.",
keywords = "Inflammation, MCP-1, Mesangial cell, Retinoic acid, Rosiglitazone",
author = "Kim, {Dae Hee} and Lee, {Geon Cheol} and Kim, {Cy Hyun} and Oh, {Se Won} and Han, {Kum Hyun} and Han, {Sang Youb}",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "28",
pages = "463--467",
journal = "Biomedical Research",
issn = "0970-938X",
publisher = "Scientific Publishers of India",
number = "1",

}

TY - JOUR

T1 - Anti-inflammatory effect of combination therapy with rosiglitazone and all-trans retinoic acid on high glucose-induced MCP-1 response in rat mesangial cells

AU - Kim, Dae Hee

AU - Lee, Geon Cheol

AU - Kim, Cy Hyun

AU - Oh, Se Won

AU - Han, Kum Hyun

AU - Han, Sang Youb

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) agonists and retinoid acid have anti-inflammatory and anti-proliferative effects; however, their synergistic effects are not well known. We investigated the combined anti-inflammatory effect of rosiglitazone, which is a PPAR-γ agonist, and retinoid acid in rat mesangial cells (RMCs) stimulated by a high glucose (HG) concentration (30 mmol of D-glucose). The doses of rosiglitazone and all-trans retinoic acid (ATRA) which inhibited MCP-1 mRNA expression by 20-40% were selected for the study. At 48 h following incubation of RMCs in HG, MCP-1 mRNA expression was significantly increased. Rosiglitazone and ATRA lowered MCP-1 mRNA expression in a dose-dependent manner. Among the effective doses, 1.0 and 5.0 μmol/L of rosiglitazone, and 0.1 and 1.0 μmol/L of ATRA were selected for further studies. HG-induced MCP-1 mRNA expression was inhibited by combined treatment with rosiglitazone and ATRA. A combination of 1.0 μmol/L rosiglitazone and 0.1 μmol/L ATRA tended to decrease MCP-1 mRNA expression compared to the individual treatments. A combination of 5.0 μmol/L rosiglitazone and 1.0 μmol/L ATRA significantly inhibited MCP-1 mRNA expression. MCP-1 protein levels were significantly increased after 48 h of incubating the RMCs in HG. The 5.0 μmol/L dose of rosiglitazone significantly lowered MCP-1 protein synthesis while 1 μmol/L ATRA decreased MCP-1 expression stimulated by HG. Combined treatment with rosiglitazone and ATRA caused a larger decrease in MCP-1 protein synthesis compared to either treatment alone. In conclusion, the data obtained show the possibility of a synergistic effect on MCP-1 mRNA expression by rosiglitazone and ATRA.

AB - Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) agonists and retinoid acid have anti-inflammatory and anti-proliferative effects; however, their synergistic effects are not well known. We investigated the combined anti-inflammatory effect of rosiglitazone, which is a PPAR-γ agonist, and retinoid acid in rat mesangial cells (RMCs) stimulated by a high glucose (HG) concentration (30 mmol of D-glucose). The doses of rosiglitazone and all-trans retinoic acid (ATRA) which inhibited MCP-1 mRNA expression by 20-40% were selected for the study. At 48 h following incubation of RMCs in HG, MCP-1 mRNA expression was significantly increased. Rosiglitazone and ATRA lowered MCP-1 mRNA expression in a dose-dependent manner. Among the effective doses, 1.0 and 5.0 μmol/L of rosiglitazone, and 0.1 and 1.0 μmol/L of ATRA were selected for further studies. HG-induced MCP-1 mRNA expression was inhibited by combined treatment with rosiglitazone and ATRA. A combination of 1.0 μmol/L rosiglitazone and 0.1 μmol/L ATRA tended to decrease MCP-1 mRNA expression compared to the individual treatments. A combination of 5.0 μmol/L rosiglitazone and 1.0 μmol/L ATRA significantly inhibited MCP-1 mRNA expression. MCP-1 protein levels were significantly increased after 48 h of incubating the RMCs in HG. The 5.0 μmol/L dose of rosiglitazone significantly lowered MCP-1 protein synthesis while 1 μmol/L ATRA decreased MCP-1 expression stimulated by HG. Combined treatment with rosiglitazone and ATRA caused a larger decrease in MCP-1 protein synthesis compared to either treatment alone. In conclusion, the data obtained show the possibility of a synergistic effect on MCP-1 mRNA expression by rosiglitazone and ATRA.

KW - Inflammation

KW - MCP-1

KW - Mesangial cell

KW - Retinoic acid

KW - Rosiglitazone

UR - http://www.scopus.com/inward/record.url?scp=85009960679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009960679&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 463

EP - 467

JO - Biomedical Research

JF - Biomedical Research

SN - 0970-938X

IS - 1

ER -